Summary
The Ninth Circuit affirmed a district court order requiring Idaho officials to provide discovery concerning the origin, manufacture, acquisition, and characteristics of execution drugs sought by Idaho death-row inmate Gerald Ross Pizzuto. The court held that it had interlocutory jurisdiction under the collateral order doctrine because disclosure of information potentially identifying the execution-drug supplier could cause irreparable harm. It further held that Idaho’s execution-secrecy statute did not create a privilege binding on a federal court in a federal-question case and that the challenged discovery was relevant and not unduly burdensome under the circumstances.
Topics
Practice areas
Questions Presented
- Whether the Ninth Circuit had jurisdiction under the collateral order doctrine to review an interlocutory discovery order concerning information that could reveal the identity of Idaho's execution-drug supplier.
- Whether the district court abused its discretion by finding Pizzuto's discovery requests relevant under the federal discovery rules.
- Whether Idaho's execution-secrecy statute created an evidentiary privilege binding on a federal court in a federal-question case.
- Whether the district court abused its discretion by applying a reasonable-degree-of-certainty standard to determine whether disclosure would unduly burden Idaho and by ordering the challenged disclosures.
Holdings
- The Ninth Circuit had jurisdiction to review the interlocutory discovery order because the order conclusively determined the disputed question, resolved an issue separate from the merits, and was effectively unreviewable after final judgment where disclosure could reveal Idaho's execution-drug supplier and irreparably impair the State's execution protocol.
- The district court did not abuse its discretion in finding relevant information about when the execution drugs were obtained, their geographic origin, the type of supplier or manufacturer, and whether Akorn manufactured them.
- Idaho Code § 19-2716A does not create an evidentiary privilege that binds federal courts in federal-question cases, and the court declined to recognize a new federal evidentiary privilege for the identity of a state's execution-drug supplier.
- Information that would reasonably lead to identification of a state's execution-drug supplier would unduly burden the State, but speculative assertions that disclosure could possibly identify the supplier are insufficient. Applying that standard, the district court did not abuse its discretion in ordering the challenged disclosures.
Key quotations
“We hold that disclosure of information that would reasonably lead to the identification of the State’s execution drug supplier unduly burdens the State.” (31)
“We are holding that here, Idaho did not show why the discovery should not be had; that is, that Idaho did not show, to the requisite degree, how its strong interest in enforcing its criminal laws, including its death penalty laws, would be inappropriately harmed or burdened by allowing the challenged discovery.” (35)
Factual background
Gerald Ross Pizzuto, an Idaho death-row inmate, alleged that his medical conditions and Idaho's lethal-injection practices created a substantial risk of serious pain and suffering in violation of the Eighth Amendment. He sought discovery about the origin, manufacture, acquisition, storage, and quality of execution drugs, including drugs Idaho obtained for another inmate's scheduled execution. Idaho invoked its execution-secrecy statute and argued that disclosure of the requested information could identify its execution-drug supplier and impair its ability to carry out executions.
Procedural history
Pizzuto brought a 42 U.S.C. § 1983 action in the District of Idaho alleging that execution by lethal injection would violate the Eighth Amendment. The district court ordered the defendants to provide specified information about the execution drugs, including acquisition dates, geographic origin, supplier type, and a Certificate of Analysis report date, while protecting information that would identify the execution-drug supplier to a reasonable degree of certainty. The defendants appealed the March 2024 discovery order, and the Ninth Circuit held that the collateral order doctrine permitted interlocutory review and affirmed.